The human metapneumovirus: A case series and review of the literature

Safi Shahda, William Carlos, P. J. Kiel, Babar Khan, Chadi Hage

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Human metapneumovirus (hMPV) is an emerging human pulmonary pathogen that is genetically related to respiratory syncytial virus. It has been increasingly associated with respiratory illnesses over the last few decades. Immunocompromised patients are particularly susceptible with resultant morbidity and mortality. We describe our experience with 9 immunocompromised patients diagnosed with pneumonia secondary to hMPV, 2 of whom were successfully treated with aerosolized and oral ribavirin along with intravenous immunoglobulin (IVIG). We suggest that hMPV should be considered in the differential diagnosis of immunocompromised patients with acute respiratory illness. Ribavirin (oral and aerosolized) with IVIG is potentially an effective treatment option for those with severe disease.

Original languageEnglish
Pages (from-to)324-328
Number of pages5
JournalTransplant Infectious Disease
Volume13
Issue number3
DOIs
StatePublished - Jun 2011

Fingerprint

Metapneumovirus
Immunocompromised Host
Ribavirin
Intravenous Immunoglobulins
Respiratory Syncytial Viruses
Pneumonia
Differential Diagnosis
Morbidity
Lung
Mortality

Keywords

  • Cellular rejection
  • Hematopoietic stem cell transplant
  • Human metapneumovirus
  • Immunosuppression
  • Lung transplant
  • Ribavirin

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Cite this

The human metapneumovirus : A case series and review of the literature. / Shahda, Safi; Carlos, William; Kiel, P. J.; Khan, Babar; Hage, Chadi.

In: Transplant Infectious Disease, Vol. 13, No. 3, 06.2011, p. 324-328.

Research output: Contribution to journalArticle

@article{a47ce20d790e43f49e9456a3a3a7cc34,
title = "The human metapneumovirus: A case series and review of the literature",
abstract = "Human metapneumovirus (hMPV) is an emerging human pulmonary pathogen that is genetically related to respiratory syncytial virus. It has been increasingly associated with respiratory illnesses over the last few decades. Immunocompromised patients are particularly susceptible with resultant morbidity and mortality. We describe our experience with 9 immunocompromised patients diagnosed with pneumonia secondary to hMPV, 2 of whom were successfully treated with aerosolized and oral ribavirin along with intravenous immunoglobulin (IVIG). We suggest that hMPV should be considered in the differential diagnosis of immunocompromised patients with acute respiratory illness. Ribavirin (oral and aerosolized) with IVIG is potentially an effective treatment option for those with severe disease.",
keywords = "Cellular rejection, Hematopoietic stem cell transplant, Human metapneumovirus, Immunosuppression, Lung transplant, Ribavirin",
author = "Safi Shahda and William Carlos and Kiel, {P. J.} and Babar Khan and Chadi Hage",
year = "2011",
month = "6",
doi = "10.1111/j.1399-3062.2010.00575.x",
language = "English",
volume = "13",
pages = "324--328",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - The human metapneumovirus

T2 - A case series and review of the literature

AU - Shahda, Safi

AU - Carlos, William

AU - Kiel, P. J.

AU - Khan, Babar

AU - Hage, Chadi

PY - 2011/6

Y1 - 2011/6

N2 - Human metapneumovirus (hMPV) is an emerging human pulmonary pathogen that is genetically related to respiratory syncytial virus. It has been increasingly associated with respiratory illnesses over the last few decades. Immunocompromised patients are particularly susceptible with resultant morbidity and mortality. We describe our experience with 9 immunocompromised patients diagnosed with pneumonia secondary to hMPV, 2 of whom were successfully treated with aerosolized and oral ribavirin along with intravenous immunoglobulin (IVIG). We suggest that hMPV should be considered in the differential diagnosis of immunocompromised patients with acute respiratory illness. Ribavirin (oral and aerosolized) with IVIG is potentially an effective treatment option for those with severe disease.

AB - Human metapneumovirus (hMPV) is an emerging human pulmonary pathogen that is genetically related to respiratory syncytial virus. It has been increasingly associated with respiratory illnesses over the last few decades. Immunocompromised patients are particularly susceptible with resultant morbidity and mortality. We describe our experience with 9 immunocompromised patients diagnosed with pneumonia secondary to hMPV, 2 of whom were successfully treated with aerosolized and oral ribavirin along with intravenous immunoglobulin (IVIG). We suggest that hMPV should be considered in the differential diagnosis of immunocompromised patients with acute respiratory illness. Ribavirin (oral and aerosolized) with IVIG is potentially an effective treatment option for those with severe disease.

KW - Cellular rejection

KW - Hematopoietic stem cell transplant

KW - Human metapneumovirus

KW - Immunosuppression

KW - Lung transplant

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=79957977434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957977434&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3062.2010.00575.x

DO - 10.1111/j.1399-3062.2010.00575.x

M3 - Article

C2 - 21631655

AN - SCOPUS:79957977434

VL - 13

SP - 324

EP - 328

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 3

ER -